Text to Voice
Forbes generated its 2017 list of most powerful women across the world, and among them are these 5 powerful business women.
1. Mary Barra:
Mary Barra, Chairman and CEO of General Motors, is known for making tough decisions in business and the one who pulled GM back from the less profitable international market. She beat Tesla's much-hyped Model 3 to market with the Chevrolet Bolt EV, which launched in 2016 with a battery that can outlast Tesla's; its now the top-selling non-luxury pure electric car. With her announcement that GM plans to move towards 100% electric cars, she is adapting to a new reality as countries such as France and the U.K. announced plans to ban gas and diesel automobiles- with China and India likely to join them.
2. Indra Nooyi:
Indra Nooyi, Chairman and CEO of Pepsico, who moves up from No. 14 to No. 11 in 2017, is responding to the long-term decline in soda drinking in the U.S. by adding to her company's healthier product lines. Adjusting to shifts in consumer habits also makes Pepsi a more attractive partner to Whole Foods, recently purchased by Amazon and ready to take on the grocery industry.
3. Marillyn Hewson:
Marillyn Hewson, Chairman, President and CEO of Lockheed Martin, was listed into the 2017 edition of Wash100 for international market focus and F-35 leadership. In 2017, she was also listed at No. 35 on the Harvard Business Review "The Best- Performing CEOs in the World 2017" list. Since becoming CEO in 2013, Lockheed's market cap has doubled. In July 2015, Hewson announced the purchase of Sikorsky Aircraft, the producers of Sikorsky UH-60 Black Hawk helicopters, giving Lockheed its own helicopter building capability. Hewson has also shifted more company efforts towards building military hardware.
4. Isabelle Kocher:
Isabelle Kocher, CEO of France-based Engie, the world's largest non-state-owned electricity company. She is rapidly transitioning Engie away from fossil fuels and toward solar energy, wind power and electric-vehicle charging stations.
5. Emma Walmsley:
Emma Walmsley, CEO of GlaxoSmithKline, is shifting more of the pharmaceutical company's drug development toward promising areas such as oncology and immune-inflammation therapy. While she fights downward pressure on drug prices, Walmsley also is navigating Brexit, preparing a backup system to test drugs in the EU if Britain is unable to successfully negotiate a new trade deal.